ArticleAnnals of hematology2025
IGH/IGK gene rearrangement in the diagnosis of B-cell non-Hodgkin lymphoma: experience from three centers.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Bilateral primary diffuse large B-cell lymphoma of the breast: diagnostic and surgical management-a case report.Gland surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
B-cell non-Hodgkin lymphomas (B-NHL) are a heterogeneous group of malignancies that pose significant diagnostic challenges due to their clinical and molecular diversity. Traditional detection methods (e.g., morphology and immunohistochemistry) could confirm most cases, but 10% remain difficult to diagnose. Comparatively, immunoglobulin clonality assessment has great potential to support the diagnosis of lymphocytic malignancies. This study retrospectively analyzed 996 patients with suspected B-NHL and reactive lymphoid hyperplasia (RLH) from three centers. Immunoglobulin heavy/light chain (IGH/IGK) gene rearrangements were detected using capillary electrophoresis, and results were compared with final diagnoses based on clinical follow-up. Among 978 cases with definitive diagnoses, 97.1% (369/380) of B-NHL patients showed IGH/IGK gene rearrangements, while 99.7% (596/598) of non-B-NHL patients were negative. The combined evaluation of morphology and IGH/IGK rearrangement improved the sensitivity from 70.8 to 98.2% and the accuracy from 81.7 to 92.1% over morphology alone. The combined assessment of morphology, immunohistochemistry and IGH/IGK rearrangement improved the sensitivity from 71.6 to 98.2% and the accuracy from 83.2 to 93.4% compared to the combined assessment of morphology and immunohistochemistry. Additionally, IGH rearrangements were more frequent than IGK rearrangements in B-NHL patients, with significant differences in rearrangement patterns among B-NHL subtypes. The IGH rearrangement was mainly found in small lymphocytic lymphomas, diffuse large B-cell lymphoma and follicular lymphoma; the IGK rearrangements were mainly found in B-cell lymphoblastic lymphomas and marginal zone lymphoma; the IGH and IGK rearrangements were mainly found in mantle cell lymphoma and multiple myeloma. In conclusion, IGH/IGK rearrangement analysis showed high consistency with final diagnoses, supporting its integration into routine clinical diagnostics to improve the accuracy of B-NHL diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.